FI3463325T3 - Mikrohiukkaset, jotka käsittävät rikkiä sisältävää yhdistettä - Google Patents

Mikrohiukkaset, jotka käsittävät rikkiä sisältävää yhdistettä Download PDF

Info

Publication number
FI3463325T3
FI3463325T3 FIEP17735616.9T FI17735616T FI3463325T3 FI 3463325 T3 FI3463325 T3 FI 3463325T3 FI 17735616 T FI17735616 T FI 17735616T FI 3463325 T3 FI3463325 T3 FI 3463325T3
Authority
FI
Finland
Prior art keywords
composition
use according
stabilizer
microparticles
microns
Prior art date
Application number
FIEP17735616.9T
Other languages
English (en)
Finnish (fi)
Inventor
Deborah O'neil
Original Assignee
Novabiotics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novabiotics Ltd filed Critical Novabiotics Ltd
Application granted granted Critical
Publication of FI3463325T3 publication Critical patent/FI3463325T3/fi

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • A61K9/1623Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/145Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Accessories For Mixers (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
  • Pigments, Carbon Blacks, Or Wood Stains (AREA)
  • Anti-Oxidant Or Stabilizer Compositions (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
FIEP17735616.9T 2016-06-07 2017-06-06 Mikrohiukkaset, jotka käsittävät rikkiä sisältävää yhdistettä FI3463325T3 (fi)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662346969P 2016-06-07 2016-06-07
GBGB1609940.0A GB201609940D0 (en) 2016-06-07 2016-06-07 Microparticles
PCT/GB2017/051637 WO2017212249A1 (en) 2016-06-07 2017-06-06 Microparticles comprising a sulphur-containing compound

Publications (1)

Publication Number Publication Date
FI3463325T3 true FI3463325T3 (fi) 2023-12-19

Family

ID=56508202

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP17735616.9T FI3463325T3 (fi) 2016-06-07 2017-06-06 Mikrohiukkaset, jotka käsittävät rikkiä sisältävää yhdistettä

Country Status (16)

Country Link
US (1) US11369568B2 (cg-RX-API-DMAC7.html)
EP (1) EP3463325B1 (cg-RX-API-DMAC7.html)
JP (1) JP7195934B2 (cg-RX-API-DMAC7.html)
KR (1) KR102412212B1 (cg-RX-API-DMAC7.html)
CN (1) CN109310654A (cg-RX-API-DMAC7.html)
AU (1) AU2017277897B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018075221B1 (cg-RX-API-DMAC7.html)
CA (2) CA3096121C (cg-RX-API-DMAC7.html)
DK (1) DK3463325T3 (cg-RX-API-DMAC7.html)
ES (1) ES2965017T3 (cg-RX-API-DMAC7.html)
FI (1) FI3463325T3 (cg-RX-API-DMAC7.html)
GB (1) GB201609940D0 (cg-RX-API-DMAC7.html)
MX (1) MX2018014278A (cg-RX-API-DMAC7.html)
SG (1) SG11201810934TA (cg-RX-API-DMAC7.html)
WO (1) WO2017212249A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201807852B (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10905660B2 (en) 2016-06-07 2021-02-02 Novabiotics Limited Microparticles
EP3572068A1 (en) * 2018-05-22 2019-11-27 RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.a. New salt of cysteamine for the preparation of highly respirable particles
DK3866775T3 (da) * 2018-10-17 2025-06-16 Novabiotics Ltd Cysteamin til anvendelse i behandling af lungesygdomme
US20230346696A1 (en) * 2020-09-03 2023-11-02 Philip Morris Products S.A. Spray dried low hygroscopicity active powder compositions
US11793808B2 (en) 2021-02-22 2023-10-24 Mannkind Corp. Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them
WO2023107996A1 (en) * 2021-12-07 2023-06-15 Cila Therapeutic Inc. Anti-viral therapeutic agents and uses thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8901570D0 (sv) 1989-05-02 1989-05-02 Draco Ab Organic salts of cysteine derivatives
KR100770362B1 (ko) 2004-12-30 2007-10-26 (주)두비엘 분무건조 고분자형 콜렉틴족 단백질 및 그의 제조방법
AR057623A1 (es) 2005-11-28 2007-12-05 Omega Bio Pharma H K Ltd Materiales y metodos para el tratamiento de las infecciones virales
CA2667072C (en) 2006-12-22 2015-11-24 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Gel useful for the delivery of ophthalmic drugs
CN101342155B (zh) * 2007-07-11 2012-01-04 天津帝士力投资控股集团有限公司 一种(r,r)-福莫特罗吸入粉雾剂及其制备方法
CA2744655A1 (en) 2008-11-27 2010-06-03 Boehringer Ingelheim International Gmbh Novel powdered crystalline medicines for inhalation
US8389021B2 (en) * 2009-02-03 2013-03-05 Microbion Corporation Bismuth-thiols as antiseptics for epithelial tissues, acute and chronic wounds, bacterial biofilms and other indications
WO2010138419A2 (en) 2009-05-23 2010-12-02 Obio Pharmaceutical (H.K.) Ltd. Materials and methods for treating viral infections
GB201021186D0 (en) 2010-12-14 2011-01-26 Novabiotics Ltd Composition
BR112013029803B1 (pt) 2011-05-19 2021-07-13 Savara, Inc Composições de vancomicina em pó seco
JP5981123B2 (ja) 2011-10-11 2016-08-31 サンサ コーポレーション (バルバドス) インク ニコチン薬の製造法およびその方法により製造される医薬
MX2014004994A (es) * 2011-10-26 2014-08-27 Seattle Children S Res Inst Cisteamina en el tratamiento de enfermedad fibrotica.
AU2013216703A1 (en) * 2012-02-10 2014-09-25 Whitehead Institute For Biomedical Research Inhibition of the glycine cleavage system for treatment of cancer
ITMI20130572A1 (it) 2013-04-10 2014-10-11 Eratech Srl Composizione comprendente almeno due polveri secche ottenute per spray dry per aumentare la stabilita' della formulazione
EP3054937B1 (en) 2013-10-11 2023-07-26 Pulmokine, Inc. Spray dry formulations
GB201416716D0 (en) 2014-09-22 2014-11-05 Novabiotics Ltd Use
ITUA20161799A1 (it) * 2016-03-18 2017-09-18 Recordati Ind Chimica E Farmaceutica S P A Composizione farmaceutica a rilascio prolungato comprendente cisteamina o un suo sale
US10905660B2 (en) * 2016-06-07 2021-02-02 Novabiotics Limited Microparticles

Also Published As

Publication number Publication date
BR112018075221B1 (pt) 2024-02-06
AU2017277897B2 (en) 2022-09-08
NZ748596A (en) 2025-06-27
US20190175501A1 (en) 2019-06-13
RU2018142841A3 (cg-RX-API-DMAC7.html) 2020-09-30
CA3026743C (en) 2024-05-28
KR102412212B1 (ko) 2022-06-23
SG11201810934TA (en) 2019-01-30
AU2017277897A1 (en) 2018-12-20
CN109310654A (zh) 2019-02-05
EP3463325A1 (en) 2019-04-10
BR112018075221A2 (pt) 2019-03-19
WO2017212249A1 (en) 2017-12-14
DK3463325T3 (da) 2024-01-02
CA3096121C (en) 2022-11-15
RU2018142841A (ru) 2020-06-04
JP2019517541A (ja) 2019-06-24
ES2965017T3 (es) 2024-04-10
KR20190016957A (ko) 2019-02-19
US11369568B2 (en) 2022-06-28
EP3463325B1 (en) 2023-11-08
ZA201807852B (en) 2023-05-31
JP7195934B2 (ja) 2022-12-26
CA3026743A1 (en) 2017-12-14
MX2018014278A (es) 2019-03-14
GB201609940D0 (en) 2016-07-20
CA3096121A1 (en) 2017-12-14

Similar Documents

Publication Publication Date Title
FI3463325T3 (fi) Mikrohiukkaset, jotka käsittävät rikkiä sisältävää yhdistettä
JP2016534153A5 (cg-RX-API-DMAC7.html)
JP2019517541A5 (cg-RX-API-DMAC7.html)
HRP20230863T1 (hr) Inhalacijska formulacija rapamicina, namijenjena liječenju stanja povezanih sa starenjem
UA107499C2 (uk) Склад сухого порошку, який містить антимускариновий засіб
JP2015509788A5 (cg-RX-API-DMAC7.html)
ZA202303338B (en) Orodispersible dosage unit containing an estetrol component
JP2012176990A5 (cg-RX-API-DMAC7.html)
SI2760821T1 (en) A salt salt of an anti-inflammatory substituted cyclobutenedione compound
JP2015525763A5 (cg-RX-API-DMAC7.html)
HRP20210749T1 (hr) Farmaceutski pripravci koji sadrže azd9291
WO2014140925A3 (en) Topical compositions and methods of treatment of topical disorders
JP2011201907A5 (cg-RX-API-DMAC7.html)
JP2016513688A5 (cg-RX-API-DMAC7.html)
WO2015003478A3 (zh) 一种适用于婴幼儿及儿童的口腔崩解片及其制备方法
IL273388B1 (en) Compositions and methods for treating and ameliorating respiratory conditions and inflammation of mucosa
JP2011157405A5 (cg-RX-API-DMAC7.html)
JP2016510326A5 (cg-RX-API-DMAC7.html)
WO2016095013A8 (en) Pharmaceutical composition comprising plasminogen and uses thereof
HRP20220683T1 (hr) Liječenje parkinsonove bolesti
HRP20221185T1 (hr) Beta-ukosnica peptidomimetik s inhibitorskom aktivnošću elastase i njegovi oblici doziranja aerosolom
HRP20201696T1 (hr) Farmaceutska parenteralna formulacija koja sadrži kargluminsku kiselinu
RU2015125313A (ru) Вакцина для защиты жвачных животных от пневмонии, вызываемой pasteurella multocida
FI3706710T3 (fi) Pitkäkestoisesti vapautuvia formulaatioita nivelensisäisiin käyttötarkoituksiin
NZ748596B2 (en) Microparticles comprising a sulphur-containing compound